AUTHOR LOGIN Close
Please enter author credentials to view Author Manual
Username:
Password:  
   
for New Author Registration
JAYPEE JOURNALS
International Scientific Journals from Jaypee
IndexCopernicus Value: 80.23
Home Instructions Editorial Board Current Issue Pubmed Archives Subscription Advertisement Contact Us
 
LOGIN  
Username: Password:
 
New Author Registration | Forgot Password ?
 
 
 
Most Downloaded Articles of the Journal
 
 
List of All Articles
1.  HYPERTENSION AND NEUROGENIC IMPACT
Hypertension and Ischemic Stroke
Sudhir Kumar
[Year:2016] [Month:January-March] [Volume:2 ] [Number:1] [Pages:53] [Pages No:39-43] [No of Hits : 975]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0028 | FREE

ABSTRACT

Stroke is among the leading causes of death and disability worldwide. Ischemic stroke is 3 to 4 times more common than hemorrhagic stroke. Hypertension is the commonest risk factor for ischemic stroke, in addition to diabetes mellitus, dyslipidemia and smoking. Blood pressure (BP) lowering with appropriate antihypertensive agents would lead to reduction of first ever stroke as well as recurrent strokes. This article discusses the epidemiology of strokes in India, role of hypertension in ischemic stroke causation and its recurrence; BP targets to be achieved, and the preferred antihypertensive agents. In addition, management of hypertension in the setting of acute ischemic stroke is also discussed. Blood pressure lowering is generally avoided within the first 24 hours after acute ischemic stroke. Proper BP management is one of the keys to ensure better outcomes in acute stroke setting.

Keywords: Antihyper tensive agents, Epidemiology, Hypertension, India, Ischemic, Prevention, Risk factor, Stroke, Stroke recurrence, Target BP.

How to cite this article: Kumar S. Hypertension and Ischemic Stroke. Hypertens J 2016;2(1):39-43.

Source of support: Nil

Conflict of interest: None

 
2.  SECONDARY HYPERTENSION
Severe Paroxysmal Hypertension: Pseudopheochromocytoma
Samuel J Mann
[Year:2016] [Month:April-June] [Volume:2 ] [Number:2] [Pages:53] [Pages No:96-102] [No of Hits : 884]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0038 | FREE

ABSTRACT

Paroxysmal hypertension always engenders a search for a catecholamine-secreting pheochromocytoma (pheo). However, in 98% of cases, a pheo is not found, and the cause and management of the paroxysmal hypertension have remained a largely unstudied mystery. This review presents an approach to understanding and successfully treating this disorder, which is increasingly known as “pseudopheochromocytoma,” or “pseudopheo.” Patients with this disorder experience sudden, unprovoked, and symptomatic blood pressure elevations that are likely linked to stimulation of the sympathetic nervous system. Psychological characteristics associated with this disorder suggest a basis in repressed emotion related either to prior emotional trauma or to a repressive (nonemotional) coping style. Based on this understanding, successful intervention is possible in most of the cases. Hypertensive paroxysms can usually be managed acutely with an anxiolytic agent, such as alprazolam, an antihypertensive agent that targets the sympathetic nervous system, such as clonidine, or a combination of the two. Severe paroxysms may require an intravenous agent, such as labetalol or nitroprusside. In patients with severe and/or frequent paroxysms, recurrence of paroxysms can be prevented in most of the cases with an antidepressant drug. The importance of reassurance cannot be overstated. The possible role of psychotherapeutic intervention requires further study. Fortunately, with appropriately selected intervention, paroxysms can be effectively treated or eliminated in most patients.

Keywords: Catecholamines, Hypertension, Labile hypertension, Paroxysmal hypertension, Pheochromocytoma, Pseudopheochromocytoma.

How to cite this article: Mann SJ. Severe Paroxysmal Hypertension: Pseudopheochromocytoma. Hypertens J 2016;2(2):96-102.

Source of support: Nil

Conflict of interest: None

 
3.  THERAPEUTIC UPDATE
Therapeutic Role of Beta-blockers in Hypertension: A Pragmatic Reappraisal
Soumitra Kumar
[Year:2016] [Month:April-June] [Volume:2 ] [Number:2] [Pages:53] [Pages No:80-85] [No of Hits : 587]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0036 | FREE

ABSTRACT

Beta-blockers have been used as first-time antihypertensives for decades and such use has also been recommended by guidelines. However, subsequently some meta-analyses questioned this status of beta-blockers by bringing to light their limitation in terms of stroke prevention and their metabolic sideeffects. Following this, several major international hypertension guidelines have removed beta-blockers from the first line of recommended drugs. Some other guidelines, however, have retained them as first-line antihypertensive. Age is an important determinant of choice of antihypertensives and beta-blockers have proven to be very useful in young hypertensives especially if overweight. Amidst these controversies, vasodilatory beta-blockers have emerged with a new promise. They are potent antihypertensives with better reduction of central aortic pressure and a neutral or favorable metabolic profile.

Keywords: Age, Metabolic effects, Stroke, Vasodilatory.

How to cite this article: Kumar S. Therapeutic Role of Betablockers in Hypertension: A Pragmatic Reappraisal. Hypertens J 2016;2(2):80-85.

Source of support: Nil

Conflict of interest: None

 
4.  HYPERTENSION AND THE KIDNEY
Hypertension in Patients with Chronic Kidney Disease
P Vijay Varma, M Rajasekara Chakravarthi, G Jyothsna
[Year:2016] [Month:January-March] [Volume:2 ] [Number:1] [Pages:53] [Pages No:28-34] [No of Hits : 578]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0026 | FREE

ABSTRACT

The prevalence of hypertension in chronic kidney disease (CKD) patients exceeds that of the general population. Uncontrolled hypertension plays a significant role in progression to end stage renal disease and results in increased cardiovascular morbidity and mortality. A complex interplay between various pathophysiologic mechanisms is responsible for the development of hypertension in this patient population. The major factors being extracellular volume overload, increased endothelin-1 release and excess renin-angiotensin-aldosterone system and sympathetic nervous system activity. Dietary and lifestyle modifications have synergistic effects to drug therapy in the control of hypertension. There is no single blood pressure target that is optimal for all CKD patients. It is important to individualize the treatment depending on age, the severity of albuminuria, and comorbidities. Drugs blocking the renin-angiotensin-aldosterone system are the recommended first-line antihypertensive agents for most CKD patients. Intradialytic hypertension may be prevented by individualizing the dialysis prescription and using nondialyzable antihypertensives. New onset of hypertension in the elderly or new onset of difficult to control hypertension in a previously well controlled hypertensive patient should prompt the work up for atherosclerotic renal vascular disease.

Keywords: Aldosterone, Angiotensin, Chronic, Hypertension, Kidney, Renin.

How to cite this article: Varma PV, Chakravarthi MR, Jyothsna G. Hypertension in Patients with Chronic Kidney Disease. Hypertens J 2016;2(1):28-34.

Source of support: Nil

Conflict of interest: None

 
5.  PATHOPHYSIOLOGY OF HYPERTENSION
Metabolic Syndrome in the Indian Population: Public Health Implications
PP Mohanan
[Year:2016] [Month:January-March] [Volume:2 ] [Number:1] [Pages:53] [Pages No:1-6] [No of Hits : 554]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0021 | FREE

ABSTRACT

Metabolic syndrome (MS) is now being increasing recognized as an emerging threat which will invade desktops of public health policy planners in the decades to come. The clusters which make this syndrome and its etiopathogenesis will keep getting varied in different ethnic populations, regions and countries. Factors like migration, socioeconomic status, lifestyle, nutrition habits play important role. Therefore, research in MS provides an interdisciplinary forum to explore the pathophysiology, recognition, and treatment of the cluster of conditions associated with the evolving entity of MS.

Keywords: Atherosclerotic, Dyslipidemia, Intramyocellular lipids.

How to cite this article: Mohanan PP. Metabolic Syndrome in the Indian Population: Public Health Implications. Hypertens J 2016;2(1):1-6.

Source of support: Nil

Conflict of interest: None

 
6.  PATHOPHYSIOLOGY
Echocardiographic Evaluation of Left Ventricular Systolic and Diastolic Function in Hypertension
Amier Ahmad, Navin C Nanda
[Year:2016] [Month:July-September] [Volume:2 ] [Number:3] [Pages:80] [Pages No:113-117] [No of Hits : 528]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0042 | FREE

ABSTRACT

Hypertension is a significant health problem, i.e., associated with considerable morbidity and mortality. The hallmark of hypertensive disease is a gradual increase in left ventricular (LV) mass, resulting in concentric hypertrophy and eventual diastolic dysfunction of the left ventricle secondary to LV stiffness and impaired relaxation. Late stages may be characterized by severe LV systolic dysfunction and dilatation. Echocardiography offers clinicians a quick, reliable, and inexpensive method of assessing changes in LV function resulting from hypertension. In this review, we summarize various echocardiographic parameters, including their advantages and disadvantages, and clinicians should be familiar with in order to ascertain an assessment of cardiovascular risk in hypertensive patients.

Keywords: Echocardiography, Hypertension, Left ventricular diastolic function, Lef t ventricular systolic function, Three-dimensional echocardiography, Two-dimensional echocardiography.

How to cite this article: Ahmad A, Nanda NC. Echocardiographic Evaluation of Left Ventricular Systolic and Diastolic Function in Hypertension. Hypertens J 2016;2(3):113-117.

Source of support: Nil

Conflict of interest: None

 
7.  NEWER THERAPEUTIC INSIGHT
Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus
Gary E Sander, Camilo Fernandez, Philip J Kadowitz, Thomas D Giles
[Year:2016] [Month:July-September] [Volume:2 ] [Number:3] [Pages:80] [Pages No:139-144] [No of Hits : 527]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0046 | FREE

ABSTRACT

Aim: To provide a perspective on the effect of Sodium-glucose co-transporter 2 (SGLT2) inhibitors on cardiovascular (CV) risk reduction in type 2 diabetes mellitus (DM) patients.

Background: Sodium-glucose co-transporter 2 inhibitors have been introduced as hypoglycemic agents for the treatment of type 2 diabetes by the unique mechanism of inhibiting the SGLT2 protein-mediated uptake of glucose by the kidney, producing an osmotic diuresis and some degree of natriuresis. The Food and Drug Administration (FDA) has thus far approved three drugs of this class for the treatment of type 2 diabetes - empagliflozin, canagliflozin, and dapagliflozin.

Review results: During the clinical trials performed to establish efficacy in diabetes control, these drugs were found to exert a range of beneficial effects beyond glucose lowering. The most interesting of these has been a reduction in systolic blood pressure (SBP) by an average of 3 to 5 mm Hg and diastolic blood pressure (DBP) of 2 to 3 mm Hg. A larger and even more unexpected discovery was that empagliflozin reduced the primary outcome of death from CV causes and nonfatal myocardial infarctions and strokes from 12.1% in the placebo group to 10.5% in an empagliflozin group in a clinical trial enrolling high CV risk patients. Overall, there was a 30 to 40% reduction in heart failure hospitalizations (HFHs) and all-cause deaths, with the event reduction appearing within the first 6 months and persisting to the trial conclusion.

Conclusion: The mechanisms for the aforementioned impressive beneficial events remain unclear, but may involve improvements in such parameters as blood pressure, vascular volume, myocardial glucose availability, reduced arterial vascular stiffness, and improvements in autonomic nervous system function. At this time, all approved SGLT2 inhibitors appear similar in pharmacological actions. Clinical trials are now in progress - or under development - that will further explore the CV actions and outcomes of these drugs.

Clinical significance: This review may aid to unify the existing knowledge on SGLT2 inhibitors and CV risk reduction, and set the path for further research endeavors to clarify mechanisms of action associated with additional CV benefits.

Keywords: Blood pressure, Cardiovascular outcomes, Cardiovascular risk, Hypertension, SGLT2 inhibitors, Type 2 diabetes mellitus.

How to cite this article: Sander GE, Fernandez C, Kadowitz PJ, Giles TD. Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. Hypertens J 2016;2(3):139-144.

Source of support: Nil

Conflict of interest: None

 
8.  Hemodynamics of hypertension
Central Aortic Blood Pressure and Pulse Wave Velocity as Additional Markers in Patients with Hypertension
Ravi R Kasliwal, Kushagra Mahansaria, Manish Bansal
[Year:2015] [Month:October-December] [Volume:1 ] [Number:2] [Pages:57] [Pages No:73-82] [No of Hits : 1346]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0013 | FREE

ABSTRACT

Arterial stiffness is a pathological manifestation of cumulative vascular damage resulting from various known and unknown vascular risk factors. Central aortic pressure and pulse wave velocity are the two most commonly used and the most informative non-invasive measures of arterial stiffness. Numerous studies have documented incremental value of these measures in a variety of clinical conditions, most notably, hypertension. In hypertensive subjects, assessment of arterial stiffness not only provides incremental information about vascular risk, it also helps in guiding therapeutic decision making and serves as a tool for monitoring response to antihypertensive therapy.

Keywords: Arterial stiffness, Arteriosclerosis, Subclinical atherosclerosis, Vascular damage.

How to cite this article: Kasliwal RR, Mahansaria K, Bansal M. Central Aortic Blood Pressure and Pulse Wave Velocity as Additional Markers in Patients with Hypertension. Hypertens J 2015;1(2):73-82.

Source of support: Nil

Conflict of interest: None

 
9.  Status Report
Hypertension as a Public Health Problem in India
Rajeev Gupta
[Year:2015] [Month:July-September] [Volume:1 ] [Number:1] [Pages:61] [Pages No:1-3] [No of Hits : 912]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0001 | FREE

ABSTRACT

Hypertension is the most important risk factor for global morbidity and mortality. It has assumed epidemic proportions in India with an estimated 100 million patients. In recent decades, the disease is increasing more rapidly in rural than in urban population. Status of hypertension treatment and control is dismal in India with about a third of patients on treatment and only 20% controlled. Innovative system-based strategies using a combination of public health approaches and physician led clinic-based management are required to prevent premature cardiovascular disease burden due to hypertension.

Keywords: Cardiovascular disease, Hypertension epidemiology, Public health approach, Risk factors.

How to cite this article: Gupta R. Hypertension as a Public Health Problem in India. Hypertens J 2015;1(1):1-3.

Source of support: Nil

Conflict of interest: None

 
10.  Therapeutics update
Hypertension Therapeutics Update: A Brief Clinical Summary on Azilsartan, Cilnidipine and Nebivolol
Sanjeev Sharma
[Year:2015] [Month:October-December] [Volume:1 ] [Number:2] [Pages:57] [Pages No:111-117] [No of Hits : 874]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0019 | FREE

ABSTRACT

Uncontrolled hypertension is the major risk factor for cardiovascular disease. The economic burden of disease is enormous in developed as well as in developing countries. The epidemiological studies have explained many etiological factors associated with chronic untreated hypertension, which varies according to geography and ethnicity.
In last five decades, many classes and types of antihypertensive drugs have been developed. This pharmacological review provides an update on new molecules belonging to three pharmacological classes of antihypertensives-angiotensin receptor blocker (azilsartan), calcium channel blocker (cilnidipine) and beta blocker (nebivolol) and their clinical implications.

Keywords: Azilsartan, Calcium channel L/N-type, Cilnidipine, Hypertension, Nebivolol, Newer drugs for hypertension, Vasodilation with Nebivolol.

How to cite this article: Sharma S. Hypertension Therapeutics Update: A Brief Clinical Summary on Azilsartan, Cilnidipine and Nebivolol. Hypertens J 2015;1(2):111-117.

Source of support: Nil

Conflict of interest: None

 
   Previous |  Next  
Logo
 
     
 
© Jaypee Brothers Medical Publishers (P) Ltd.
logo